1. Simposio
Simposio
"Prevención Cardiovascular Global. Un Desafío
"Prevención Cardiovascular Global. Un Desafío
Permanente“
Permanente“
Reduciendo el Colesterol ¿Cuál es el Límite?
Reduciendo el Colesterol ¿Cuál es el Límite?
Dr. Alvaro Sosa Liprandi MTSAC FACC
Dr. Alvaro Sosa Liprandi MTSAC FACC
Jefe de Cardiología Director Director
Sanatorio Güemes Instituto Cardiovascular Lezica Instituto Cardiovascular Austral
Buenos Aires San Isidro, Buenos Aires Ushuaia, Tierra del Fuego
Buenos Aires. Septiembre 2012
2. XIII Jornadas de Cardiología del Litoral
XIII Jornadas de Cardiología del Litoral
“Prevención del Riesgo Cardiovascular Global.
“Prevención del Riesgo Cardiovascular Global.
Un concepto consolidado”
Un concepto consolidado”
Reduciendo el Colesterol ¿Cuál es el Límite?
Reduciendo el Colesterol ¿Cuál es el Límite?
Dr. Alvaro Sosa Liprandi MTSAC FACC
Dr. Alvaro Sosa Liprandi MTSAC FACC
Jefe de Cardiología Director Director
Sanatorio Güemes Instituto Cardiovascular Lezica Instituto Cardiovascular Austral
Buenos Aires San Isidro, Buenos Aires Ushuaia, Tierra del Fuego
Santa Fé. Septiembre 2012
3. Jornadas Interdistritales del Conurbano
Riesgo Cardiovascular Global. Un concepto
Riesgo Cardiovascular Global. Un concepto
consolidado
consolidado
Reduciendo el Colesterol ¿Cuál es el Límite?
Reduciendo el Colesterol ¿Cuál es el Límite?
Dr. Alvaro Sosa Liprandi MTSAC FACC
Dr. Alvaro Sosa Liprandi MTSAC FACC
Jefe de Cardiología Director Director
Sanatorio Güemes Instituto Cardiovascular Lezica Instituto Cardiovascular Austral
Buenos Aires San Isidro, Buenos Aires Ushuaia, Tierra del Fuego
Buenos Aires, Agosto 2012
4. Vigilancia de enfermedades no transmisibles y factores de riesgo
Mortalidad por causas en las Américas año 2000
Países muy avanzados en su Países no avanzados en su
transición epidemiológica Argentina transición epidemiológica
100
83.2% 62.3% 51.5%
80
% AVAD
60
40
30
0
muy baja en niños y baja en niños y baja alta en niños y alta
muy baja en adultos en adultos en adultos
Traumatismos Enf. Transmisibles, afecciones maternas y Enf. No Transmisibles
perinatales y carencias nutricionales
5. Enfermedades No Transmisibles
Argentina
Tasa de mortalidad general 7,48 por mil
Varones 8,32 por mil
Mujeres 6,68 por mil
Tasa de mortalidad por causas
Enf. cardiovasculares 247 por 100.000 34%
Cáncer 150 por 100.000 20%
Enf. infecciosas 63 por 100.000 8%
Causas externas 51 por 100.000 7%
Todas las demás causas 236 por 100.000 31%
0 50 100 150 200 250
5 de cada 10 muertes son por CV y Cáncer
Mortalidad Prematura: 30 % de los AVPP son por CV y Cáncer
Fuente: Indicadores básicos Argentina 2001
6. Causas de muerte en la Argentina
(Tasa de mortalidad anual 1980-2004)
450
TbrMA por 100.000 habitantes
400 * * 27 % reducción
350 p<00001
300
*
250 Enf. cardiovascular
200
150 Tumores malignos
Enf. respiratorias
100
50
Accidentes
0
86
00
94
80
82
84
88
90
92
96
98
02
04
19
19
19
19
19
19
19
19
19
19
20
20
20
Sosa Liprandi MI y col. Rev Argent Cardiol 2006; 74:297-303
7. Entidades clínicas responsables de la
Mortalidad Cardiovascular. Frecuencia Relativa (%)
% 35 30,2 30,4
30 Insuficiencia
24,2 Cardíaca
25 22 Enf cerebrovascular
20
15 IAM
14
15
Enf. Coronaria
10 6 5,8 5,9
3,5 HTA
5
0
1990 2003
Sosa Liprandi MI y col. Rev Argent Cardiol 2006
8. Estimación del riesgo cardiovascular global
RIESGO RIESGO CV
GENÉTICO CLÍNICO
(Factores (Factores de
heredofamiliares) Riesgo)
RIESGO CV RIESGO CV
BIOQUÍMICO
TISULAR
(Marcadores de (Marcadores de
riesgo
riesgo tisular)
bioquímicos)
9. Evaluacion del Riesgo Cardiovascular Global
Factores Riesgo vs Estimación del Riesgo
Factores de riesgo Scores de Riesgo
LDL Enfermedad
HDL Vascular Alto Riesgo
Hipertension
Diabetes Equivalentes
Tabaco
PCR
Lp(a) Varios FRC Score
Sme.Metabolico
Homocisteina
ApoB/ApoA
Historia Familiar
Sedentarismo 0-1 FRC Bajo Riesgo
Stress
F. Psico-Sociales
?
Shape Task Force Report Am. J. Cardiology Julio 17, 2006
10. Tendencias en las Tasas de Mortalidad Cardiovascular
y el PBI en Argentina. 1995-2005
Crisis del SE Caída de la
* Asiático Convertibilidad
500
474,89
438,37
450 435,62
442,26
429,66 406,63 406,65
400 383,65
396,6
TMCV 357,54
esperada
350 TMCV
356,29
*-25%
304,76
300 277,4
288,1
279,1
276,2
264
PBI NETO
256 278,4 256
243,2
250
235,2
200
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Sosa Liprandi MI y col. Rev Arg Cardiol 2012
11. Tendencias de las Tasas de Mortalidad Cardiovascular (TMCV)
y el Producto Bruto Interno (PBI). Argentina, 1995-2005
500
474,9 Crisis del SE Asiático Caída de la Convertibilidad
450 442,3 438,4
429,7 435,6
406,6 406,6
396,6 TMCV*
400 383,6
350
356,3 357.5 Valores de las TMCV
300 288,1 279,1
304,76 y del PBI neto por año
277,4 278,4 276,2
264 256
256 * por 100.000 habitantes
243,2 235,2
250
PBI neto
A
200
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Observed
300.0
295.0 Slope 1 = 17.18
290.0
Modelo con 2 joinpoint
285.0 Slope 2 = -12.90
280.0 Slope 3 = 19.88
en la tendencia del PBI
275.0
PBI 270.0
265.0
P=0.001
260.0
255.0
250.0
245.0
B
240.0
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
470 Observed
460
450 Slope 1 = -17.74
440 Slope 2 = -6.80
Modelo con 2 joinpoint
430
Slope 3 = -16.73
420
TMCV 410
en la tendencia de la TMCV
400
390
P=ns
380
370
360 C
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
12. Evaluacion Indirecta vs. Directa
Factores Riesgo vs Presencia de Enfermedad
Carótida: IMT
Factores de riesgo
Carótida y Aorta:
detección de placa
por RMN
LDL Test
estructurales
HDL Coronarias: Score
Hipertension de calcio por TC
Diabetes
Tabaco
MMII: Índice Tobillo brazo
PCR
Lp(a)
Sme.Metabolico Braquial: vasoreactividad
Homocisteina medida por doppler
ApoB/ApoA
Historia Familiar Compliance vascular: Test
Sedentarismo medida por tonometría Funcionales
Stress
? VOP Velocidad de
Onda de Pulso
Shape Task Force Report Am. J. Cardiology Julio 17, 2006
13. PCR: Implicancia pronóstica
Muerte Cardiaca - IAM
Stroke
Muerte Cardiaca
IAM
Angina inestable
Angina inestable - IAM
0 1,0 2,0 3,0 4,0 5,0
Riesgo relativo (mayor vs menor quintilo)
Ridker PM et al. N Engl J Med 2000;342:836-843
14. PROVE IT-TIMI 22 Trial
Estatinas.Tratamiento intensivo
vs moderado en SCA
IAM ó Muerte de acuerdo a niveles alcanzados de C-LDL ó PCR
0.10 0.10
IM recurrente o muerte coronaria (%)
C-LDL > 70 mg/dl PCR > 2 mg/dl
0.08 0.08
0.06 0.06
0.04 0.04 PCR < 2 mg/dl
C-LDL < 70 mg/dl
0.02 0.02
0.00 0.00
0.0 0.5 1.0 1.5 2.0 2.5 0.0 0.5 1.0 1.5 2.0 2.5
Seguimiento (años)
Ridker PM y col. N Engl J Med 2005; 352: 20-8
15. PROVE IT-TIMI 22 Trial
Estatinas.Tratamiento intensivo
vs moderado en SCA
Relación entre niveles alcanzados de C-LDL y PCR luego
de 30 días de tratamiento con estatinas
0.10
10
CRP (mg/l)
1
0.1
30 80 130 180
C-LDL (mg/dl)
Ridker PM y col. N Engl J Med 2005; 352: 20-8
16. PROVE IT-TIMI 22 Trial
Estatinas.Tratamiento intensivo
vs moderado en SCA
IAM ó Muerte de acuerdo a niveles alcanzados de C-LDL y PCR
0.10 LDL > 70 mg/dl, PCR > 2 mg/dl
IM recurrente o muerte coronaria (%)
0.08 LDL > 70 mg/dl, PCR < 2 mg/dl
LDL < 70 mg/dl, PCR > 2 mg/dl
0.06
LDL < 70 mg/dl, PCR < 2 mg/dl
0.04 LDL < 70 mg/dl, CRP < 1 mg/dl
0.02
0.00
0.0 0.5 1.0 1.5 2.0 2.5
Seguimiento (años)
Ridker PM y col. N Engl J Med 2005; 352: 20-8
17. PROVE IT-TIMI 22 Trial
Estatinas.Tratamiento intensivo
vs moderado en SCA
IAM ó Muerte de acuerdo a niveles alcanzados de C-LDL y PCR
0.10
IM recurrente o muerte coronaria (%)
LDL > 70 mg/dl, PCR > 2 mg/dl
0.08 Objetivo doble no alcanzado
0.06
LDL < 70 mg/dl, PCR < 2 mg/dl
Objetivo doble alcanzado
0.04 LDL < 70 mg/dl, PCR < 1 mg/dl
Objetivo doble alcanzado máx.
0.02
0.00
0.0 0.5 1.0 1.5 2.0 2.5
Seguimiento (años)
Ridker PM y col. JACC 2005; 45: 1644-8
18. PCR. Es sólo un marcador inflamatorio?
Encontrada en íntima ateroesclerótica
pero no en la normal
Inducción de activación Inducción en la producción de moléculas
del complemento de adhesión, MCP-1, ET-1
Reclutamiento de monocitos Atenuación de la producción de NO
dentro de la pared arterial Disminución en la expresión de eNOS
Inducción de la producción de
Factor Tisular en monocitos
Inducción en la expresión de PAI-1
Estabilización del PAI-1 mRNA
Inducción de vasoreatividad Inducción en la oxidación de
endotelial Colesterol LDL
Mediador en el uptake de LDL
por macrófagos
19. JUPITER
Trial Design
JUPITER
Multi-National Randomized Double Blind Placebo Controlled Trial of
Rosuvastatin in the Prevention of Cardiovascular Events
Among Individuals With Low LDL and Elevated hsCRP
MI
Rosuvastatin 20 mg (N=8901) Stroke
No Prior CVD or DM
Men >50, Women >60 Unstable
LDL <130 mg/dL Angina
4-week Placebo (N=8901) CVD Death
hsCRP >2 mg/L run-in CABG/PTCA
Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Costa Rica,
Denmark, El Salvador, Estonia, Germany, Israel, Mexico, Netherlands,
Norway, Panama, Poland, Romania, Russia, South Africa, Switzerland,
United Kingdom, Uruguay, United States, Venezuela
Ridker et al, Circulation 2003;108:2292-2297.
28. JUPITER. Eventos Cardiovasculares de acuerdo a
tratamiento asignado y LDL alcanzada
Placebo
Rosuvastatina LDL > 50
Rosuvastatina LDL < 50
Hsia J et al J Am Coll Cardiol 2011; 57: 1666-75
29. JUPITER. Relación entre eventos cardiovasculares y LDL
alcanzada a 1 año en Estudios de Prevención Primaria
Hsia J et al J Am Coll Cardiol 2011; 57: 1666-75
30.
31.
32. Hipertensos: >160 TAS o >100 TAD, 40-79 a, Mas 3 FR CV como:
HVI, ECG anormal, DBT , EVP, TIA, Varon, >55 a,
microalbuminuria, fumadores, TC/HDL>6, AHF EC precoz
Estructura Internacional
Gothenburg
•
•
London
33. ASCOT: Dislipemia + HTA Tratada x 2 ramas
R = Randomizados
18,000 pacientes
R
9000 β-bloq ± diuretico 9000 BCC ± IECA
5000 Colesterol (≤250
mg/dL)
4000 Colesterol (>250
mg/dL) + 4000 Colesterol (>250
mg/dL)
5000 Colesterol (≤250
mg/dL)
500
500
Abierto x
Abierto x 4500 4500
lipidos
lipidos
R R
2250 8000 2250
2250 placebo 2250 placebo
Atorvast Abierto x Lipidos Atorvastat
Hipertensos: >160 TAS o >100 TAD, 40-79 a, 3+ FR CV como:
HVI ,ECG anormal, DBT , EVP, TIA, Varon, >55 a, microalbuminuria., fumadores,
TC/HDL>6, AHF EC precoz
34. Ascot: Punto final primario: IAM no fatal y EC fatal
Atorvastatina 10 mg Eventos 100
4
Placebo Eventos 154
Cumulative Incidence (%)
3 36% de
reduccion
2
1
HR = 0.64 (0.50-0.83) p=0.0005
0
0,0 0,5 1,0 1,5 2,0 2,5 3,0 3,5
Years
ACV: 27 % de reduccion P= 0.0236
35. CARDS: Collaborative Atorvastatin Diabetes Study
Poblacion de pacientes Atorvastatina 10 mg
Diabetes mellitus tipo 2 (n=1428)
Ambos sexos 40–75 años
2838 4-años de seguim
pacientes
Placebo doble ciego
Prevencion primaria de (n=1410)
Eventos coronarios, ACV
Puntos Finales
Primarios: tiempo hasta el primer evento CV
LDL-C ≤160 mg/dL
(muerte coronaria, IAM no fatal , angina
TG ≤600 mg/dL inestable, paro resuscitatado, revascularizacion
≥1 FR adicional coronaria, ACV
– HTA o treatmiento
– Retinopatia
Secundarios: mortalidad total , cualquier punto
– Albuminuria final CV, lipidos y lipoproteinas
Colhoun HM et al. Lancet 2004;364:685-696.
36. CARDS: Efecto de Atorvastatina en el Punto Final
Primario: Eventos CV mayores Incluyendo ACV
Reduccion de Riesgo Relativa 37%
(95% CI, 17–52) p = 0.001
15
Riesgo Cumulativo, (%)
Placebo
127 events
10
5
Atorvastatin
83 events
0
0 1 2 3 4 4.75
Años
Placebo 1410 1351 1306 1022 651 305
Atorvastatin1428 1392 1361 1074 694 328
Colhoun HM et al. Lancet 2004;364:685-696.
37. Estatinas en prevención primaria. Metaanálisis
Beneficios en función del riesgo
(N = 175 000)
Baseline risk (risk of CV Risk reduction (95% CI) per
event over five years), % 1-mmol LDL reduction
<5 0.57 (0.36-0·89)
5-10 0.61 (0.50-0·74)
10-20 0.77 (0.69-0·85)
20-30 0.77 (0.71-0·83)
20-30 0.78 (0.72-0·84)
Overall 0.76 (0.73-0·79)
CTT. Lancet 2012
40. PROVE IT - TIMI 22:
Study Design
4,162 patients with an Acute Coronary Syndrome < 10 days
ASA + Standard Medical Therapy
Double-blind
“Standard Therapy” “Intensive Therapy”
Pravastatin 40 mg Atorvastatin 80 mg
2x2 Factorial: Gatifloxacin vs. placebo
Duration: Mean 2 year follow-up (>925 events)
Primary Endpoint: Death, MI, Documented UA requiring hospitalization,
revascularization (> 30 days after randomization), or Stroke
41. Changes from (Post-ACS) Baseline in
Median LDL-C
120 Median LDL-C (Q1, Q3)
95 (79, 113)
100
Pravastatin 40mg
21% 62 (50, 79)
LDL-C 80
(mg/dL)
60
Atorvastatin 80mg
49%
40
P<0.001
20
<24h Rand. 30 Days 4 Mos. 8 Mos. 16 Mos. Final
Note: Changes in LDL-C may differ from prior trials:
• 25% of patients on statins prior to ACS event
• ACS response lowers LDL-C from true baseline
42. All-Cause Death or Major CV Events
in All Randomized Subjects
30
Pravastatin 40mg
25 (26.3%)
20
% with
Atorvastatin 80mg
Event 15 (22.4%)
10
16% RR
5 (P = 0.005)
0
0 3 6 9 12 15 18 21 24 27 30
Months of Follow-up
43. Primary Endpoint Over Time
Events Rates
RR Atorva 80 Prava 40
30 Days 17% 1.9% 2.2%
90 Days 18% 6.3% 7.7%
180 Days 14% 12.2% 14.1%
End of Follow-up 16% 22.4%* 26.3%*
0.5 0.75 1.0 1.25
1.5
Atorvastatin 80mg Better Pravastatin 40mg Better *2-year event rates
45. The Treating to New Targets (TNT) Study:
Rationale
30
Patients with CHD events (%)
25 TNT
20
Screening
?
15
10 Atorvastatin 10 mg
Atorvastatin 80 mg
5
0
70 90 110 130 150 170 190 210
LDL-C, mg/dL
Adapted from Kastelein JJP. Atherosclerosis. 1999;143 (suppl 1):S17-S21
46. TNT: Study Design
Patient population: Primary efficacy outcome measure:
CHD Time to occurrence of a major CV event:
LDL-C: 130-250 mg/dL (3.4-6.5 mmol/L) – CHD death
Triglycerides ≤600 mg/dL (≤6.8 mmol/L) – Nonfatal, non-procedure-related MI
– Resuscitated cardiac arrest
– Fatal or nonfatal stroke
Baseline
Screening Open-label run-in Double-blind period
and wash-out n=15,464 n=10,001
n=10,001
n=18,469 LDL-C <130 mg/dL (<3.4 mmol/L)
n=5006 Atorvastatin 10 mg
Atorvastatin 10 mg LDL-C target: 100 mg/dL (2.6 mmol/L)
n=4995 Atorvastatin 80 mg
LDL-C target: 75 mg/dL (1.9 mmol/L)
1-8 weeks 8 weeks Median follow-up = 4.9 years
Adapted from LaRosa JC et al. N Engl J Med. 2005;352:epub.
47. TNT: Changes in Lipids
Adapted from LaRosa JC et al. N Engl J Med. 2005;352:epub.
48. TNT: Endpoints
P<.001 P=.002
,%
,%
,%
P<.001
,%
P=.02
Adapted from LaRosa JC et al. N Engl J Med. 2005;352:epub.
49. REVERSAL: Study Design
502 symptomatic coronary artery disease patients with elevated LDL-C
Randomized, double-blind, multicenter
Aggressive lipid-lowering strategy Moderate lipid-lowering strategy
Atorvastatin (80 mg) Pravastatin (40 mg)
n=253 n=249
Endpoints (follow-up 18 months)
• Primary: percent change in atheroma volume on IVUS between baseline and 18-mo
follow-up
• Secondary: absolute change in atheroma volume, change in percent obstructive
volume
IVUS = Intravascular Ultrasonography.
Adapted from Nissen SE, et al. JAMA. 2004;291:1071-1080.
50. REVERSAL: Atheroma Regression
Pre-Statin Post-Statin
EEM Area EEM Area
13.2 mm2 11.43 mm2
5.07
mm2 5.18
mm2
Atheroma Area 8.13 mm2 Atheroma Area 6.31 mm2
Adapted from Nissen SE, et al. JAMA. 2004;291:1071-1080.
51. REVERSAL: Atheroma Regression
Change in atheroma volume Change in percent obstruction volume
P=.02, atorvastatin vs P=.0002, atorvastatin vs
4 2
pravastatin pravastatin
1.6
3 2.7
2
2
1
1
1
0
0.2
-0.4
-1 0
Atorvastatin Pravastatin
Adapted from Nissen SE, et al. JAMA. 2004;291:1071-1080.
52. Significant Benefit in Lowering LDL-C below 100
mg/dL with Atorvastatin 80 mg
30
4S-P
Patients with CHD events (%)
25
20
4S-S
LIPID-P
15
CARE-P
LIPID-S
HPS-P
10 CARE-S
HPS-S TNT: Atorvastatin 10 mg
5 TNT: Atorvastatin 80 mg S = statin treated
P = placebo treated
0
70 90 110 130 150 170 190 210
LDL-C (mg/dL)
Adapted from LaRosa JC et al. N Engl J Med. 2005;352:epub.
53. Tratamiento intensivo vs. moderado. Metaanálisis
Niveles de colesterol LDL
Muerte o Infarto
Cannon CP. JACC 2006
58. Tratamiento intensivo vs. moderado. Metaanálisis
Beneficio en función de reducción de LDL
Baigent C, CTT. Lancet 2010
59. Atorvastatina y ACV en el SPARCL : Stroke
Prevention by Aggressive Reduction of Cholesterol Levels
Pacientes
ACV /TIA 1-6 meses Placebo
previos
4,200
Pacientes
LDL 100-190 mg/dl atorvastatina 80 mg
Exclusiones:
5 years
<18 years
Hx of EC
Endarterectomia
Punto final primario
•Tiempo hasta 1ªACV fatal o no-fatal
•Punto final secundario: Eventos
coronarios mayores o eventos CV
60. SPARCL: Eventos coronarios y ACV
30
20% RRR
HR 0.80 (0.69–0.92) Placebo NNT = 29
20 P = 0.002 pacientes
Eventos por 5 años
Mayores
CV*
10 Atorvastatina
(%)
0
0 1 2 3 4 5 6
Tiempo desde randomizacion (años)
*Cardiac death, MI, resuscitated
SPARCL Investigators. N Engl J Med. 2006;355:549-59.
cardiac arrest, and stroke
61. SPARCL: Reduccion Ev. coronarios mayores
10
8
35% RRR Placebo
HR 0.65 (0.49–0.87)
Major 6
P = 0.003
coronary
events* 4
(%)
Atorvastatin
2
0
0 1 2 3 4 5 6
Time since randomization (years)
*Cardiac death, MI, resuscitated cardiac arrest SPARCL Investigators. N Engl J Med. 2006;355:549-59.
63. Solamente el 38.3% de los pacientes hospitalizados
por SCA entre 2005 y 2009, recibieron terapia
intensiva con estatinas.
64. Seguridad de Atorvastatina: Perfil de seguridad
comparable a Placebo y a otras estatinas
Todas las otras
Atorvastatina estatinas
Placebo (todas dosis) combinadas
Sistema n=1789 n=9416 n=5526
Digestivo 4% 8% 9%
Cualquier efecto adverso 5% 5% 6%
Musculoesquelético 1% 3% 3%
Neurológico 2% 3% 3%
Cutáneo 1% 2% 2%
Metabólico/nutricional 1% 1% 1%
Efectos muy raros <1% 1% <1%
Urogenital 1% 1% 1%
CV 2% 1% 1%
Newman CB, et al. Am J Cardiol. 2003;92:670-676. Data on file, Pfizer Inc.
64
65. Seguridad de Atorvastatina:
No Relación Dosis-Respuesta con los EAs
Porcentaje de pacientes que experimentaron
≥ 1 evento adverso a dosis fija por grupo
20
16
15 15
15
13
Pacientes (%)
10
8
5
0
Placebo 10 mg 20 mg 40 mg 80 mg
n = 293/1949 n = 839/6343 n = 19/242 n = 30/186 n = 344/2345
Atorvastatina
Newman CB, et al. Am J Cardiol. 2003;92:670-676. Data on file, Pfizer Inc.
65
66. Seguridad de Atorvastatina: Baja Tasa de Descontinuación
Debido a EAs por Placebo, Atorvastatina y otras Estatinas
Datos Agrupados de los Estudios
5
sacados de los estudios debido
a AEs asociados al tratamiento)
% de pacientes que fueron
4 3.6
3 2.6
2
0.9
1
0
Placebo Atorvastatina Todas las otras
n = 16/1789 (todas dosis) estatinas combinadas
n = 241/9416 n = 198/5526
Newman CB, et al. Am J Cardiol. 2003;92:670-676. Data on file, Pfizer Inc.
66
67. Seguridad de Atorvastatina: No Relación
Dosis-Respuesta para Mialgia
Dosis Fija Agrupada
6
Pacientes experimentaron
4
mialgia (%)
3.2
2.7
2.6
2.0
2
1.5
0
Placebo 10 mg 20 mg 40 mg 80 mg
n = 30/1949 n = 173/6343 n = 5/242 n = 30/186 n = 61/2345
Atorvastatina
Newman CB, et al. Am J Cardiol. 2003;92:670-676. Data on file. Data on file, Pfizer Inc.
67
68. EAs Musculoesqueléticos a través del rango de
dosis
Atorvastatina
Placebo 10 mg 20 mg 40 mg 80 mg
n=1949 n=6343 n=242 n=186 n=2345
Mialgia 2% 3% 2% 3% 2%
Artralgia 1% 2% 0% 3% 1%
Artritis 1% 1% 2% 0% <1%
Alteración articular <1% <1% 0% 1% <1%
Miopatia* 0% 0% 0% 0% 0%
*En vigilancia postmarketing, raros casos de miopatia y rabdomiolisis han sido reportados con atorvastatina y otras estatinas.
Newman CB, et al. Am J Cardiol. 2003;92:670-676. Data on file, Pfizer Inc.
68
69. Seguridad de Atorvastatina: Baja Ocurrencia de
Elevaciones Persistentes de ALT/AST
Dosis Fija Agrupada
1.0% 0.89%
0.8%
Pacientes (%)
0.6%
0.4% 0.40%
0.2%
0.0% 0.13% 0.12%
10 mg 20 mg 40 mg 80 mg
En promedio, 0.5% de los pacientes tratados con atorvastatina
experimentaron incrementos de los valores de ALT/AST
Newman CB, et al. Am J Cardiol. 2003;92:670-676. Data on file, Pfizer Inc.
69
70. RABDOMIOLISIS
DOSIS DOSIS ALTAS
ESTANDAR
PROVE IT 0% 0%
A to Z 0% 0,13%
TNT 0.06% 0.04%
IDEAL 0.07% 0.05%
J Am Coll Cardiol 2006; 48: 438-445
71. CPK TOTAL > 10 LSN
DOSIS DOSIS ALTAS
ESTANDAR
PROVE IT 0,10% 0,15%
A to Z 0,04% 0,4%
TNT 0% 0%
IDEAL 0% 0%
J Am Coll Cardiol 2006; 48: 438-445
72. ALT/AST > 3 LSN
DOSIS DOSIS ALTAS
ESTANDAR
PROVE IT 1,1% 3,3%
A to Z 0,36% 0,84%
TNT 0,18% 1,2%
IDEAL 0,16% 1,37%
J Am Coll Cardiol 2006; 48: 438-445
73. Resumen de los efectos adversos
• Riesgo de rabdomiolisis: 0.05%
• Riesgo de miopatías: 0.15%
• Riesgo de elevacion de AST/ALT: 3.3%
• Riesgo de mialgias: 5 a 15%
• Porcentaje de pacientes que deben
suspender la terapia: < 9%
74. Factores de riesgo que aumentan los
efectos adversos de las estatinas
• Edad > 75 años
• Medicamentos concomitantes
– Fibratos
– Macrólidos
– Antifúngicos
– Ciclosporina
• Ingesta de alcohol
• Disfunción hepática o renal
76. Estudio Saturno. Regresión Ateroesclerosis
Atorvastatina vs rosuvastatina
Nicholls SJ. N Engl J Med 2011; 365: 2078
77. Evolución de las guias terapéuticas
NCEP NCEP NCEP
ATP
1970s ATP I ATP II ATP III 04 IV
1988 1993 2001 2012
Framingham Angiograficos WOSCOPS, Improve It
MRFIT (FATS, POSCH, 4S,CARE, TNT, IDEAL
LFC-CPPT SCOR, STARS, LIPID, A to Z,
Coronary Drug Omish, MARS) AFCAPS, HPS,Jupiter
Project Meta-Analisis VA-HIT, SPARCL
Helsinki (Holme, Rossouw) Otros PROSPER
ASCOT
MIRACL
78. Reduciendo el Colesterol ¿Cuál es el Límite?
Conclusiones
El uso de estatinas se asocia a una marcada reducción en la tasa combinada
de mortalidad y eventos vasculares en el seguimiento, tanto en prevención
primaria como secundaria.
No ha podido establecerse un umbral de tratamiento
¨Cuanto mas bajo mejor¨
En Prevención Primaria, la estratificación del riesgo clínico como criterio
de selección de pacientes para tratamiento con estatinas, debe ser validado
En prevención secundaria, el tratamiento intensivo es marcadamnete
superior al moderado
No hay diferencias entre las distintas estatinas en términos de efectividad
clínica
79. Reducción del RR de mortalidad de diferentes estrategias
de prevención secundaria del IAM
Betabloqueantes
Freemantle N et al 23%
BMJ 1999; 318: 1730-1737
Estatinas
Pignone M et al 29%
BMJ 2000; 321: 983-986
IECA
Flather MD et al 23%
Lancet 2000; 355: 1575-1581
Aspirina
Collaborative Meta-analysis 15%
BMJ 2002; 324: 71-86
Cesación de tabaco
Critchley JA et al 36%
JAMA 2003; 290: 86-97
0 10 20 30 40 50
% RR
80. It is time for cardiologists to be less passive about
their patients’ smoking status and public health
approaches to tackle smoking. After all, a reduction in
smoking at the patient and population level would
have a bigger impact on cardiovascular disease than
any of the high-tech interventions delegates in
Orlando will hear about. ■ The Lancet 2009; 373: 867.
Cardiologists should be less passive about smoking cessation
81. Reduciendo el Colesterol ¿Cuál es el Límite?
Conclusiones
Huang Dee: Nai - Ching (2600 B.C)
1st Chinese Medical Text
• Los buenos médicos previenen la enfermedad.
• Los mediocres tratan la enfermedad antes que ésta se haga
evidente
• Los malos sólo lo hacen frente a su presencia.
Notas del editor
Argentina se encuentra en proceso de transición epidemiológica.Usando como indicador los años de vida ajustados por discapacidad se observa que Nuestro pais esta en un punto intermedio entre los paises mas avanzados y los menos avanzados en el proceso de transicion (estamos a mitad de camino)
Hoy se puede ver la estructura de la arteria sin necesidad de poner un pedazo de arteria en el microscopio, con el eco. (mas adelante hay un ejemplo mejor)
PAD Prevalence > 55 Years The blue bars in the graph show the prevalence of PAD, confirmed by an ankle-brachial index value of less than 0.9, as reported in six different studies. Overall, age-adjusted prevalence of PAD is approximately 12%, affecting men and women about equally. Claudication was present in 1% to 6% of the subjects, depending on the study. The six studies by and large enrolled patients older than 55 years; however, one of the six, by Zheng et al, enrolled patients between the ages of 45 and 64 years. In this study, the prevalence of PAD and claudication was by far the lowest of any of the six studies. Five of the six studies also tracked the prevalence of clinical cardiovascular disease (CVD). In the studies enrolling older patients (>55), CVD prevalence ranged between 33% and 56%. Patients with PAD, even when they do not have a history of previous MI or ischemic stroke, are at approximately equal risk of death from cardiovascular causes as are patients with a history of coronary or cerebrovascular disease. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med . 2001;344:1608-1621.
Mortalidad Cv y crisis económica Se observa la tendencia de la tasa de Mortalidad CV en la población mayor de 35 años en el período 1995-2005: se observa una tendencia a la reducción de la mortalidad desde 1995 hasta 1997 coincidiendo con el incremento neto del PBI anual. En 1997 , 1998 y 1999 se observa un incremento en la tasa de mortalidad anual, coincidiendo con la crisis asiática, que se manifiesta sobre todo en 1999. El acmé de descenso neto del PBI que se observa en el 2002, coincide con un comportamiento inverso en la curva de mortalidad. A partir de ese momento se observa un incremento en el PBI que se acompaña de un descenso o plateau de la curva de mortalidad.
PAD Prevalence > 55 Years The blue bars in the graph show the prevalence of PAD, confirmed by an ankle-brachial index value of less than 0.9, as reported in six different studies. Overall, age-adjusted prevalence of PAD is approximately 12%, affecting men and women about equally. Claudication was present in 1% to 6% of the subjects, depending on the study. The six studies by and large enrolled patients older than 55 years; however, one of the six, by Zheng et al, enrolled patients between the ages of 45 and 64 years. In this study, the prevalence of PAD and claudication was by far the lowest of any of the six studies. Five of the six studies also tracked the prevalence of clinical cardiovascular disease (CVD). In the studies enrolling older patients (>55), CVD prevalence ranged between 33% and 56%. Patients with PAD, even when they do not have a history of previous MI or ischemic stroke, are at approximately equal risk of death from cardiovascular causes as are patients with a history of coronary or cerebrovascular disease. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med . 2001;344:1608-1621.
Core Unmet Need (CM) 09/28/12 21:54 3
Core Unmet Need (CM) 09/28/12 21:54 ASCOT employs a 2x2 factorial design, which allows 2 hypotheses to be tested simultaneously. The first hypothesis tested is whether a newer antihypertensive regimen (calcium channel blocker [CCB] ± an angiotensin-converting enzyme inhibitor [ACE]) is more effective than a standard regimen ( -blocker ± a diuretic) in the primary prevention of CHD in hypertensive patients. The second hypothesis tested is whether a statin, compared with placebo, would provide protection against CHD endpoints in hypertensive subjects with normal to moderately elevated levels of TC ( 6.5 mmol/L [ 250 mg/dL]). The ASCOT study is structured in the following manner (target numbers): An estimated sample size of 18,000 patients was required to generate 1150 primary endpoints, giving the study 80% power to detect treatment effects. Of these 18,000 patients, it was intended that 9000 would be randomized to receive therapy with a CCB (amlodipine) ± an ACE (perindopril) and 9000 would be randomized to a -blocker (atenolol) ± a diuretic (bendroflumethiazide+potassium). Of the approximately 9000 patients randomized to the -blocker ± diuretic arm, 5000 patients were expected to have TC levels of 6.5 mmol/L ( 250 mg/dL) and 4000 patients were expected to have TC levels of >6.5 mmol/L (>250 mg/dL). Approximately 500 patients with TC 6.5 mmol/L ( 250 mg/dL) were assigned to open lipid-lowering therapy; the remaining 4500 patients were randomized to therapy with atorvastatin 10 mg/d or placebo. Similarly, of the 9000 patients randomized to therapy with CCB ± ACE, 5000 patients were expected to have TC 6.5 mmol/L ( 250 mg/dL) and 4000 patients were expected to have TC >6.5 mmol/L (>250 mg/dL). All 8000 patients from both antihypertensive arms with TC >6.5 mmol/L (>250 mg/dL) would be assigned to open lipid-lowering therapy (usual care). As in the -blocker ± diuretic arm, the 5000 patients in the CCB ± ACE arm with TC 6.5 mmol/L ( 250 mg/dL) were assigned to open lipid-lowering therapy (n=500) or were randomized to therapy with atorvastatin 10 mg/d (n=2250) or placebo (n=2250).
Core Unmet Need (CM) 09/28/12 21:54 The primary end point of nonfatal MI (including silent MI) and fatal CHD was significantly lower by 36% (hazard ratio 0.64, CI 0.5 – 0.83, p=0.005) in the atorvastatin group compared with the placebo group.
Core Unmet Need (CM) 09/28/12 21:54
Core Unmet Need (CM) 09/28/12 21:54
PROVE IT is a double-blind, randomized trial that has enrolled 4,160 patients, at approximately 400 sites in the US, Europe, Canada, and Australia, who have experienced an acute coronary syndrome (Q wave and non-Q-wave MI or unstable angina) within the previous 10 days. Patients received either 40 mg of pravastatin or 80 mg of atorvastatin within 10 days of their event and were followed for a mean follow-up period of 2 years. To study the role of infection in ACS, one half of the patients in the trial also received gatifloxacin 400 mg in addition to either pravastatin or atorvastatin. Gatifloxacin was started on day 15 after the initial episode of ACS for a treatment period of 14 days. Gatifloxacin was subsequently given as a pulsed dose of 400mg per day for 10 days each month for a mean of 2 years. The other half of the patient population received an antibiotic placebo.
4
In order to answer this question, we evaluated a large group of patients with established, stable coronary heart disease. First we reduced their LDL to a target of around 100mg/dL with atorvastatin 10mg. Then we randomized the group, leaving half on 10mg of atorvastatin daily, and giving the other half 80mg of atorvastatin daily in order to further reduce their LDL to a target of around 75mg/dL. We wanted to record the impact of this intervention on the incidence of major cardiovascular events.
So, we tested the TNT hypothesis in a double-blind, parallel-group design. We screened a total of 18,469 patients at 256 sites in 14 countries. Lipid lowering therapy was withdrawn, and all patients entered a wash-out phase. 15,432 patients with established CHD and with an LDL-C level of between 130 and 250 mg/dL and with triglycerides less than or equal to 600 mg/dL were then eligible to enter the 8-week open-label run-in period with atorvastatin 10 mg/day . In order to ensure that we had two groups that met our LDL targets, and because it would have been unethical to under treat patients whose LDL remained above 130, we entered only those patients with a mean LDL-C that was less than 130mg/dL on 10 mg of open label atorvastatin into the randomized phase of the study. We randomized 10,001 patients to double-blind therapy with either atorvastatin 10 or 80 mg/day. 5006 patients remained on atorvastatin 10mg daily, and 4995 patients received 80mg daily. Using t he time of randomization is as the baseline for the study, patients were then followed for a median of 4.9 years. The primary efficacy outcome measure was the time to occurrence of a major cardiovascular event, defined as CHD death, nonfatal non-procedure-related MI, resuscitated cardiac arrest, and fatal or nonfatal stroke.
In conclusion, we have entered a new era in the treatment of established coronary heart disease. Treating patients with established CHD to an LDL of 77mg/dL with 80mg of atorvastatin daily, from their starting LDL of 100, provided a highly significant reduction in the risk of major cardiovascular events. The event rates recorded in both arms of the TNT study are lower than those achieved in any of the other major secondary prevention studies. The results of the TNT study indicate that the quantitative relationship between reduced LDL cholesterol and reduced CHD risk demonstrated in prior statin secondary prevention trials holds true even at very low LDL cholesterol levels. Significant declines in CHD and cardiovascular morbidity were observed in the atorvastatin 80mg group relative to the atorvastatin 10 mg group. This improved clinical outcome is achieved without significant additional safety risk - even with atorvastatin 80 mg, there was a very low incidence of elevated LFTs or myalgias and there were no definite cases of rhabdomyolysis with high-dose atorvastatin. These data extend the growing body of evidence indicating that lowering LDL cholesterol well below currently recommended levels can further reduce the preventable healthcare burden associated with cardiovascular and cerebrovascular disability. Thank you.
Core Unmet Need (CM) 09/28/12 21:54 Click to add text
Core Unmet Need (CM) 09/28/12 21:54 Click to add text
Analysis of adverse events (AEs) data for the fixed-dose data grouping showed that the proportion of patients experiencing at least 1 AE was similar to placebo at each atorvastatin dose. There was no dose-response relationship in the overall incidence of AEs to atorvastatin exposure across the 10-80 mg dose range. Newman CB, et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol . 2003;92:670-676 . Data on file, Pfizer Inc. Review of 44 completed clinical trials.
The incidence of discontinuations due to AEs demonstrated in the analysis of the pooled data was low. Only 2.6% of atorvastatin-treated patients, compared with 3.6% of patients receiving other statins, withdrew from studies due to treatment-associated AEs. Newman CB, et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol . 2003;92:670-676 . Data on file, Pfizer Inc. Review of 44 completed clinical trials.
Analysis of the fixed-dose data grouping found that the incidence of myalgia did not increase across the atorvastatin dose range, and at each dose the proportion of patients experiencing the event was similar to that seen in the patients treated with placebo. Only 1 patient receiving atorvastatin in this group of 44 studies experienced persistent CPK elevations > 10 x ULN. The patient had no other AEs associated with the elevated enzymes. The patient was a 16-year-old male with severe hypercholesterolemia and a history of xanthomas, hypertension, occasional headaches, and slightly elevated creatine kinase levels who had received treatment with atorvastatin 40 mg/d for 28 days followed by treatment with atorvastatin 80 mg/d for 479 days. Study medication was continued and by the end of the study the elevated levels of CPK had returned to baseline. Newman CB, et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol . 2003;92:670-676 . Data on file, Pfizer Inc. Review of 44 completed clinical trials.
These data are based on a patient population that experienced > 3 x ULN ALT/AST elevations occurring on 2 consecutive occasions within 14 days. An analysis of completed studies showed a low occurrence of persistent ALT/AST elevations. On average, 0.5% of patients treated with atorvastatin 10, 20, 40, and 80 mg experienced increased ALT/AST values. The incidence of elevated ALT/AST values ranged from 0.13% in the atorvastatin 10-mg group to 0.89% in the atorvastatin 80-mg group. The average value for placebo was 0.28% (5/1789). Newman CB, et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol . 2003;92:670-676 . Data on file, Pfizer Inc. Review of 44 completed clinical trials.
Core Unmet Need (CM) 09/28/12 21:54
En la revisión sistemática de Julia Critchley evaluación de 20 estudios demostraron una reducción del RR del 36% de mortalidad de toda causa en pacientes con ECV que abandonaron comparado con los que continuaron fumando. Este 36% de reducción parece tanto o mas impactante que otras intervenciones en prevención secundaria como el uso de BB post IAM, estatinas para bajar los niveles de colesterol, grupo colaborativo de uso de IECA en IAM, meta-análisis sobre la utilidad de anti-agregación para prevención de mortalidad, IAM y Stroke. En un estudio mas reciente de Mohiuddin publicado en CHEST 2007 la reducción del RR de mortalidad total fue del 77% a dos años en el grupo de tratamiento intensivo comparado con un grupo con intervención mínima. Estos eran paciente entre 35 a 75 años hospitalizados en UCO con SCA o IC. La reducción del Riesgo absoluto de mortalidad fue de 9,2% y el numero necesario de tratar fue de 11